Theriva Biologics, Inc. (TOVX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
TOVX Revenue Analysis (2013–2024)
As of March 4, 2026, Theriva Biologics, Inc. (TOVX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, TOVX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including ARMP (-7.6% YoY), EVGN (-26.2% YoY), and SYBX (-100.0% YoY). Compare TOVX vs ARMP →
Peer Comparison
Compare TOVX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TOVXCurrent | $0 | - | - | - | |
 ARMP | $5M | -7.6% | - | -820.2% | |
 EVGN | $9M | -26.2% | +62.4% | -255.4% | |
 SYBX | $8,000 | -100.0% | -67.6% | -511875.0% | |
 ELAB | $2M | -179.8% | - | -75.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-26,346,000 | - |
| 2023 | $0 | - | $0 | - | $-21,431,000 | - |
| 2022 | $0 | - | $0 | - | $-21,581,000 | - |
| 2021 | $0 | - | $0 | - | $-14,274,000 | - |
| 2020 | $0 | - | $0 | - | $-10,160,000 | - |
| 2019 | $0 | - | $0 | - | $-15,663,000 | - |
| 2018 | $0 | - | $-272,000 | - | $-17,571,000 | - |
| 2017 | $0 | - | $-245,000 | - | $-26,251,000 | - |
| 2016 | $0 | - | $-157,000 | - | $-39,252,000 | - |
| 2015 | $0 | - | $-72,000 | - | $-40,980,000 | - |
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TOVX vs AGIO
See how TOVX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TOVX's revenue growth accelerating or slowing?
TOVX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is TOVX's long-term revenue growth rate?
Theriva Biologics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is TOVX's revenue distributed by segment?
TOVX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.